
Published
03 November 2010 | By Exploristics
There is great expectation in the Pharmaceutical Industry that the era of personalised medicine will deliver safer and more effective treatments (Jørgensen & Winther, 2009). This promise is made possible by the emergence of new technologies and data acquisition platforms that can generate enormous amounts of patient-level biomarker data to characterise biological processes and explain response to treatment.
As a registered user of PBR you can skip the majority of this form. Registration is FREE so register now or log in if you're already a member.
Fill In Details
By clicking the 'download white paper' button you agree to pass your details as shown to the white paper advertiser. The enquirer also permits the advertiser to follow up the enquiry by phone or email. PBR is in no way responsible for further communication between parties.
Fields marked * are compulsory
Fields marked * are compulsory